Guidelines for Testosterone Replacement Therapy (TRT) Refills

Initial Follow-up Timeline

• The European Association of Urology recommends that the first follow-up evaluation should occur at 3 months after starting TRT when sexual symptoms typically begin to improve 1, 2
• Subsequent monitoring should be time-dependent and varies according to the specific testosterone preparation used 1

Required Monitoring Parameters

Clinical Assessment

• Evaluate improvement in hypogonadal symptoms (sexual function, energy levels, mood) 1
• Monitor for adverse effects including erythrocytosis, which occurs in up to 44% of patients receiving injections 3
• Assess for signs of polycythemia, which requires withdrawal of treatment and phlebotomy in high-risk cases 1

Laboratory Testing

• Measure serum testosterone levels 2-3 months after initiation of treatment 3
• Monitor hematocrit/hemoglobin to detect polycythemia 1, 4
• Check PSA levels, particularly in men over 40 years old 4, 5

Formulation-Specific Considerations

Injectable Testosterone

• May cause fluctuating testosterone levels requiring more careful monitoring 3
• Higher risk of polycythemia compared to transdermal formulations 3
• More economical option ($156.24 annually vs. $2,135.32 for transdermal) 6

Transdermal Formulations (Gels/Patches)

• Provide more stable testosterone levels 4
• Lower risk of polycythemia compared to injections 4
• More expensive than injectable options 6

Refill Decision Algorithm

• Verify efficacy by confirming testosterone levels are within mid-normal physiological range (14-17.5 nmol/L) and assessing symptomatic improvement 1, 2, 4
• Safety assessment includes checking hematocrit (discontinue if >54%) and monitoring PSA (significant increases require further evaluation) 1, 2

Contraindications to Continued TRT

• Active or treated male breast cancer 1
• Men actively seeking fertility (standard TRT suppresses spermatogenesis) 1
• Significant adverse effects including erythrocytosis 1
• Significant PSA increases requiring further evaluation 1

Long-term Considerations

• Evidence on long-term benefits or harms is limited due to studies with relatively short follow-up periods 6
• Regular monitoring is essential as evidence about mortality remains inconclusive 6
• Patient compliance is crucial for this lifelong treatment, with discontinuation rates between 30-62% reported 6